Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Mercy Cancer Center at Mercy Medical Center
2054
mi
from 98109
Canton, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Mercy Cancer Center at Mercy Medical Center
2054
mi
from 98109
Canton, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Aultman Hospital
2055
mi
from 98109
Canton, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Aultman Hospital
2055
mi
from 98109
Canton, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Case Western Reserve Univ
2024
mi
from 98109
Cleveland, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
2024
mi
from 98109
Cleveland, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Metro Health Medical Center
2021
mi
from 98109
Cleveland, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Metro Health Medical Center
2021
mi
from 98109
Cleveland, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
St. Rita's Medical Center
1932
mi
from 98109
Lima, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
St. Rita's Medical Center
1932
mi
from 98109
Lima, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Natalie W Bryant Cancer Center
1558
mi
from 98109
Tulsa, OK
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Natalie W Bryant Cancer Center
1558
mi
from 98109
Tulsa, OK
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Bryn Mawr Hospital
2363
mi
from 98109
Bryn Mawr, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Bryn Mawr Hospital
2363
mi
from 98109
Bryn Mawr, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Geisinger Medical Center
2273
mi
from 98109
Danville, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Geisinger Medical Center
2273
mi
from 98109
Danville, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Geisinger Cancer Center
2302
mi
from 98109
Hazelton, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Geisinger Cancer Center
2302
mi
from 98109
Hazelton, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Paoli Memorial Hospital
2355
mi
from 98109
Paoli, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Paoli Memorial Hospital
2355
mi
from 98109
Paoli, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Abamson Cancer Center of the University of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Abamson Cancer Center of the University of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Geisinger Medical Group - State College
2221
mi
from 98109
State College, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Geisinger Medical Group - State College
2221
mi
from 98109
State College, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Geisinger Wyoming Valley Medical Center
2297
mi
from 98109
Wilkes-Barre, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Geisinger Wyoming Valley Medical Center
2297
mi
from 98109
Wilkes-Barre, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
CCOP - Main Line Health
2366
mi
from 98109
Wynnewood, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
CCOP - Main Line Health
2366
mi
from 98109
Wynnewood, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Lankenau Cancer Center at Lankenau Hospital
2366
mi
from 98109
Wynnewood, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Lankenau Cancer Center at Lankenau Hospital
2366
mi
from 98109
Wynnewood, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Parkland Health & Hospital Systems
1676
mi
from 98109
Dallas, TX
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Parkland Health & Hospital Systems
1676
mi
from 98109
Dallas, TX
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
1682
mi
from 98109
Dallas, TX
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
1682
mi
from 98109
Dallas, TX
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Dean Medical Center - Madison
1611
mi
from 98109
Madison, WI
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Dean Medical Center - Madison
1611
mi
from 98109
Madison, WI
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Oconomowoc Memorial Hospital
1658
mi
from 98109
Oconomowoc, WI
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Oconomowoc Memorial Hospital
1658
mi
from 98109
Oconomowoc, WI
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Waukesha Memorial Hospital
1671
mi
from 98109
Waukesha, WI
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Waukesha Memorial Hospital
1671
mi
from 98109
Waukesha, WI
Photodynamic Therapy (PDT) in Lung Cancer
An Evaluation of the Effectiveness of Photodynamic Therapy (PDT) Compared to Surgical Resection in Early Stage Roentgenographically Occult Lung Cancer.
Status: Archived
Mayo Clinic Rochester
1450
mi
from 98109
Rochester, MN
Photodynamic Therapy (PDT) in Lung Cancer
An Evaluation of the Effectiveness of Photodynamic Therapy (PDT) Compared to Surgical Resection in Early Stage Roentgenographically Occult Lung Cancer.
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
1450
mi
from 98109
Rochester, MN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Hardin Memorial Hosptial
1954
mi
from 98109
Elizabethtown, KY
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Updated: 1/1/1970
Hardin Memorial Hosptial
1954
mi
from 98109
Elizabethtown, KY
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
The Jones Clinic - Germantown
1877
mi
from 98109
Germantown, TN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Updated: 1/1/1970
The Jones Clinic - Germantown
1877
mi
from 98109
Germantown, TN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Jackson-Madison County Hospital
1900
mi
from 98109
Jackson, TN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Updated: 1/1/1970
Jackson-Madison County Hospital
1900
mi
from 98109
Jackson, TN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Baptist Regional Cancer Center at Baptist Riverside
2109
mi
from 98109
Knoxville, TN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Updated: 1/1/1970
Baptist Regional Cancer Center at Baptist Riverside
2109
mi
from 98109
Knoxville, TN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Vanderbilt-Ingram Cancer Center
1971
mi
from 98109
Nashville, TN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Updated: 1/1/1970
Vanderbilt-Ingram Cancer Center
1971
mi
from 98109
Nashville, TN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Vanderbilt-Ingram Cancer Center - Cool Springs
1980
mi
from 98109
Franklin, TN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Updated: 1/1/1970
Vanderbilt-Ingram Cancer Center - Cool Springs
1980
mi
from 98109
Franklin, TN
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Clinical Research Facility
1113
mi
from 98109
Scottsdale, AZ
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1113
mi
from 98109
Scottsdale, AZ
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Memorial Hospital of Rhode Island
2485
mi
from 98109
Pawtucket, RI
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Memorial Hospital of Rhode Island
2485
mi
from 98109
Pawtucket, RI
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Clinical Research Facility
2730
mi
from 98109
Miami, FL
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2730
mi
from 98109
Miami, FL
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Clinical Research Facility
1969
mi
from 98109
Cincinnati, OH
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1969
mi
from 98109
Cincinnati, OH
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Clinical Research Facility
149
mi
from 98109
Portland, OR
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
149
mi
from 98109
Portland, OR
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Clinical Research Facility
1661
mi
from 98109
Fort Worth, TX
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1661
mi
from 98109
Fort Worth, TX
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Clinical Research Facility
2
mi
from 98109
Seattle, WA
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2
mi
from 98109
Seattle, WA
Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer
An Open-Label Phase II Study of Zometa as Adjuvant Treatment of Malignant Pleural Effusion Due to Non-Small Cell Lung Cancer
Status: Archived
Rochester General Hospital
2160
mi
from 98109
Rochester, NY
Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer
An Open-Label Phase II Study of Zometa as Adjuvant Treatment of Malignant Pleural Effusion Due to Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Rochester General Hospital
2160
mi
from 98109
Rochester, NY
Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
Assessing Hypoxia by 18F-EF5 PET Scanning and Glycolysis by 18FFDG PET Scanning in Subjects With Non-Small Cell Lung Cancer
Status: Archived
Abamson Cancer Center of the University of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
Assessing Hypoxia by 18F-EF5 PET Scanning and Glycolysis by 18FFDG PET Scanning in Subjects With Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Abamson Cancer Center of the University of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Phase II Study of Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
2377
mi
from 98109
Basking Ridge, NJ
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Phase II Study of Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
2377
mi
from 98109
Basking Ridge, NJ
Immunotoxin Therapy, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
A Phase I Trial of SS1 ( dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma
Status: Archived
National Cancer Institute (NCI)
2315
mi
from 98109
Bethesda, MD
Immunotoxin Therapy, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
A Phase I Trial of SS1 ( dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
2315
mi
from 98109
Bethesda, MD
Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)
A Study of Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer
Status: Archived
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)
A Study of Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma
A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma
Status: Archived
National Institutes of Health Clinical Center
2315
mi
from 98109
Bethesda, MD
A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma
A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma
Status: Archived
Updated: 1/1/1970
National Institutes of Health Clinical Center
2315
mi
from 98109
Bethesda, MD
Breathing Synchronized PET/CT Scans for the Detection of Lung Lesions and Assessment of Tumor Glycolysis
The Use of Breathing Synchronized PET/CT Scans for the Detection of Lung Lesions and Assessment of Tumor Glycolysis
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
2377
mi
from 98109
Basking Ridge, NJ
Breathing Synchronized PET/CT Scans for the Detection of Lung Lesions and Assessment of Tumor Glycolysis
The Use of Breathing Synchronized PET/CT Scans for the Detection of Lung Lesions and Assessment of Tumor Glycolysis
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
2377
mi
from 98109
Basking Ridge, NJ
Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors
OS09328 Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors
Status: Archived
University of Wisconsin-Madison, Department of Dermatology
1617
mi
from 98109
Madison, WI
Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors
OS09328 Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors
Status: Archived
Updated: 1/1/1970
University of Wisconsin-Madison, Department of Dermatology
1617
mi
from 98109
Madison, WI
Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC
A Phase I Dose Escalation Study of RAD001 in Combination With Chemotherapy and Radiation in Patients With NSCLC
Status: Archived
University of Chicago Medical Center
1737
mi
from 98109
Chicago, IL
Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC
A Phase I Dose Escalation Study of RAD001 in Combination With Chemotherapy and Radiation in Patients With NSCLC
Status: Archived
Updated: 1/1/1970
University of Chicago Medical Center
1737
mi
from 98109
Chicago, IL
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
Study of BAY43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-small Cell Lung Cancer (NSCLC)
Status: Archived
Hematology Oncology Associates of the Quad Cities
1609
mi
from 98109
Bettendorf, IA
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
Study of BAY43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
1609
mi
from 98109
Bettendorf, IA
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
Study of BAY43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-small Cell Lung Cancer (NSCLC)
Status: Archived
Clinical Trial Facility
1770
mi
from 98109
Austin, TX
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
Study of BAY43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1770
mi
from 98109
Austin, TX
Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors
A Pilot, Phase II , Open Label, Nonrandomized, Multi- Center Study of [F 18]HX4 Positron Emission Tomography (PET) to Detect Hypoxia in Tumors
Status: Archived
Holy Name Medical Center
2395
mi
from 98109
Teaneck, NJ
Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors
A Pilot, Phase II , Open Label, Nonrandomized, Multi- Center Study of [F 18]HX4 Positron Emission Tomography (PET) to Detect Hypoxia in Tumors
Status: Archived
Updated: 1/1/1970
Holy Name Medical Center
2395
mi
from 98109
Teaneck, NJ
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Vanderbilt-Ingram Cancer Center - Cool Springs
1980
mi
from 98109
Franklin, TN
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Updated: 1/1/1970
Vanderbilt-Ingram Cancer Center - Cool Springs
1980
mi
from 98109
Franklin, TN
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Vanderiblt University Medical Center
1971
mi
from 98109
Nashville, TN
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Updated: 1/1/1970
Vanderiblt University Medical Center
1971
mi
from 98109
Nashville, TN
Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer
A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Were Previously Treated With First Line Chemotherapy
Status: Archived
Dana-Farber / Harvard Cancer Center
2485
mi
from 98109
Boston, MA
Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer
A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Were Previously Treated With First Line Chemotherapy
Status: Archived
Updated: 1/1/1970
Dana-Farber / Harvard Cancer Center
2485
mi
from 98109
Boston, MA
Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer
A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Were Previously Treated With First Line Chemotherapy
Status: Archived
Clinical Research Facility
2730
mi
from 98109
Miami, FL
Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer
A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Were Previously Treated With First Line Chemotherapy
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2730
mi
from 98109
Miami, FL